FASLG and ovarian cancer: Ovarian cancer-derived exosomes may impair anti-tumor immunity by carrying FasL/Fas (166), and FasL on ascites-derived exosomes in patients with epithelial ovarian cancer, as well as TRAIL, affects the presence of membranous forms of related ligand and partially explains lymphocyte apoptosis (39).